Physician profile
David M Chadbourne
NPI 1740277011
$969.25
in general payments reported to CMS, 2019-2025
28 companies · $20.00 in 2025
The $20.00 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.69 · 2020: $232 · 2021: $534 · 2022: $49.98 · 2023: $80.99 · 2025: $20.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $100.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $137.86 | 2020-2022 | |
| Astellas Pharma US INC | $132.75 | 2019-2021 | |
| Coloplast Corp | $81.73 | 2019-2021 | |
| Ethicon US, LLC | $62.50 | 2023 | Mega Soft |
| Biogen, INC. | $59.15 | 2021 | |
| Alexion Pharmaceuticals, INC. | $54.50 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $41.00 | 2020-2021 | |
| Csl Behring | $35.44 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $32.81 | 2020-2021 | |
| Ucb, INC. | $29.06 | 2021 | |
| Adamas Pharmaceuticals, INC. | $26.38 | 2020-2021 | |
| Daiichi Sankyo INC. | $23.89 | 2022 | |
| Acorda Therapeutics, INC | $21.87 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $21.06 | 2021 | |
| Calyxo, INC. | $20.00 | 2025 | Cvac Aspiration System |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $18.49 | 2023 | Xiaflex |
| Jazz Pharmaceuticals INC. | $18.14 | 2021 | |
| Blue Earth Diagnostics | $17.98 | 2021 | |
| Myriad Genetic Laboratories, INC. | $17.28 | 2021 | |
| Amgen INC. | $16.67 | 2021 | |
| Neurocrine Biosciences, INC. | $16.40 | 2021 | |
| Upsher-Smith Laboratories LLC | $14.16 | 2020 | |
| Avanir Pharmaceuticals, INC. | $13.83 | 2020 | |
| Paratek Pharmaceuticals, INC. | $13.76 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.50 | 2019 | |
| Abbvie INC. | $13.04 | 2021 | |
| Ferring Pharmaceuticals INC. | $12.18 | 2019 | |
| Travere Therapeutics, INC. | $3.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Chadbourne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.